Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Berubicin vs Lomustine in Recurrent Glioblastoma Multiforme
2024-517660-27-00Phase 2Completed
- Sponsor
- CNS Pharmaceuticals
- Start
- Sep 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, open-label trial of berubicin in glioblastoma (GBM) (2 arms), sponsored by CNS Pharmaceuticals. Primary endpoint: Overall survival. Started Sep 2022; status: completed.
02
Drugs
berubicin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2024-517660-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517660-27-00.